Compare Avantis US Small Cap Value ETF (AVUV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Moderna, Inc. — how do they compare? Avantis US Small Cap Value ETF trades at $127.78, while Moderna, Inc. trades at $63.69 (market cap $24.18B). The key difference: Avantis US Small Cap Value ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AVUV | MRNA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $128.74 | $81.80 |
52-Week Low | $93.93 | $22.36 |
Market Cap | — | $24.18B |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV, a U.S. small-cap value ETF, trades at $127.51, up 0.4% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights its strong 2026 performance, outpacing the Russell 2000, and positioning it as a diversification tool for tech-heavy portfolios. The fund benefits from a shift toward value stocks and potential rate cut tailwinds.
The outlook for AVUV is positive, driven by small-cap value momentum and investor rotation away from large-cap concentration. Key risks include sensitivity to interest rates, regional bank exposure, and higher small-cap volatility. Analyst sentiment is optimistic, with media coverage emphasizing its role in balanced long-term strategies.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
